DISCOUNT ZERTIFIKAT - BOSTON SCIENTIFIC | Market Closed - Börse Stuttgart 15:03:54 2024-05-31 EDT | ||
| 58.52 EUR | -0.09% |
|
| 3 months | +4.59% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BOSTON SCIENTIFIC CORPORATION
More news
| Date | Price | Change |
|---|---|---|
| 24-05-31 | 58.52 | -0.09% |
| 24-05-30 | 58.57 | -0.22% |
| 24-05-29 | 58.7 | +0.62% |
| 24-05-28 | 58.34 | -.--% |
| 24-05-27 | 58.34 | -0.31% |
Delayed Quote Börse Stuttgart
Last update May 31, 2024 at 03:03 pm
More quotesStatic data
| Product type | Discount Certificates |
|---|---|
| Buy / Sell | CALL |
| Underlying | BOSTON SCIENTIFIC CORPORATION |
| Issuer | Morgan Stanley |
| WKN | ME7GY1 |
| ISIN | DE000ME7GY17 |
| Date issued | 2024-01-24 |
| Maturity | 2024-09-20 (110 Days) |
| Parity | 1 : 1 |
| Emission price | 54.02 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 58.81 € |
|---|---|
| Lowest since issue | 52.88 € |
| Spread | 0.01 € |
| Spread % | 0.02% |
Company Profile
Boston Scientific Corporation specializes in the design, manufacturing and marketing of medical equipment and materials. Net sales break down by area of application as follows:
- cardiovascular (60.6%): products used in cardiology surgeries (27.4% of net sales), cardiac rhythm management (25.2%), peripheral surgeries (23.9%), electrophysiology tests (9.1%) and other (14.4%);
- endodontic surgery (37.4%): equipment used in endoscopy (45.8% of net sales), urology (36.2%) and other (18%) ;
- neuromodulation (2%).
The United States account for 59.2% of net sales.
Sector
-
Ratings for Boston Scientific Corporation
Trading Rating
Investor Rating
ESG Refinitiv
A-
Consensus: Boston Scientific Corporation
Sell
Buy
Mean consensus
BUY
Number of Analysts
32
Last Close Price
75.57
USD
Average target price
82.06
USD
Spread / Average Target
+8.59%
- Stock Market
- Certificates
- Certificat
